Deliver Your News to the World

CRO Partnering for Compound Profiling in Drug Discovery


Leipzig (Germany), March 13, 2006

NIMBUS Biotechnology announces at the 10th DRUG DISCOVERY TECHNOLOGY Europe 2006 in London, the establishment of a new partnership with NoAb BioDiscoveries in Europe. NIMBUS Biotechnology will offer the established Drug Discovery services of NoAb BioDiscoveries in Europe in addition to their fast and reliable NIMBUS Screening services.
The alliance will encompass the co-promotion of the in vitro and in vivo pharmacokinetic capabilities of NoAb BioDiscoveries together with the TRANSIL® based assays offered by NIMBUS.

During the meeting, NIMBUS Biotechnology will present at booth #1714 the new wide range of in vitro ADMET assays (e.g., cell permeability assays, metabolic stability, Cytochrome P450 inhibition, and cytotoxicity studies), as well as standard and specialized in vivo pharmacokinetic studies in rats and mice.

Wolfgang Lerch, CEO of NIMBUS Biotechnology, stated today, “NIMBUS Biotechnology is closing an important gap. “Just married: in vitro and in silico“ – will be still our slogan for NIMBUS Screening. Now we have a strong and reliable partner for the future support of our customers by providing a full range of compound profiling and a maximum of information for selection decisions at all stages of drug discovery.”

“NoAb BioDiscoveries is committed to providing the highest quality drug discovery services”, commented Mr. Dan Lichtman, CEO of NoAb BioDiscoveries. “We have established a strong reputation in North America, and look forward to future collaborations in Europe”.

NIMBUS Biotechnology is a leading provider of high-throughput ADME assays based on their proprietary TRANSIL® technology for assessing ADME related parameters and for the prediction of ADME behaviour of new chemical entities. NIMBUS Screening, their service department, provides an unique combination of in vitro assays and in silico prediction by physiology-based pharmacokinetic modeling. Hereby the customer receives a maximum of initial information about compound’s ranking and supports their decisions at all stages of drug discovery.

About NoAb BioDiscoveries
NoAb BioDiscoveries is a well-established CRO in Mississauga (Toronto), Canada which provides Pharmacokinetics/ADME services for Drug Discovery. NoAb has introduced new specialized In vivo pharmacokinetic models in rats and mice, as well as offering In vitro ADME-Tox testing services including cell permeability, plasma protein binding, Cytochrome P450 inhibition, metabolic stability studies (hepatocytes, subcellular fractions, CYP’s), and cytotoxicity studies.

NIMBUS Biotechnology GmbH
Dr. Joachim Nöller
Eilenburger Strasse 4
D-04317 Leipzig
Phone +49 341 52044 13
Fax +49 341 52044 12

NoAb BioDiscoveries Inc.
Dr. David Lee
8-2820 Argentia Road
Mississauga, ON L5N 8G4
Tel. +1 905 814-5238 x229
Fax +1 905 814-5241


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.